Scalper1 News
Specialty-drug giant Allergan (AGN) beat analysts’ Q3 estimates Wednesday as CEO Brent Saunders dodged questions about buyout talks with Pfizer (PFE) while defending the company’s drug-pricing strategies and distancing its model from its peer Valeant Pharmaceuticals International (VRX). Allergan’s sales rose 90% over the year-earlier quarter to $4.09 billion, about $50 million above analysts’ consensus, according to Thomson Reuters. Earnings Scalper1 News
Scalper1 News